about
Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinomaPrimary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeSelective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cellsDecrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesSodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors.In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma.Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.Characterization of compound 584, an Abl kinase inhibitor with lasting effects.IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells.Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression.Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells.Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation.Inhibition of RET tyrosine kinase by SU5416.Effect of imatinib on haematopoietic recovery following idarubicin exposure.Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.Water-soluble derivatives of 4-oxo-N-(4-hydroxyphenyl) retinamide: synthesis and biological activity.Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosurea on spontaneous metastases of a non-immunogenic murine tumourCD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID miceEffect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumorsIn vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitorPlacental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primatesAge- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone
P50
Q24309898-A360BFE4-6912-4EB5-BD2D-1B3CF0CEA0EBQ27853295-E7E58CAE-FFAF-4C55-B4DC-FEC2F39FF8D0Q28208972-A9B8C24E-D205-47CF-9181-FB4F22CF554FQ28366043-7DB36B72-B0FD-4EF9-8D17-7FD4C7441A73Q28488869-2D397FAF-CCCF-4C92-BE56-260CF0AB8B62Q33605066-B98F8F5E-EE59-4B06-AAF8-ABB5ACF87324Q34582817-85CFA3D0-6B7A-494C-A645-18D242B9D7AEQ36466230-08A04DBC-2DF2-4451-92B8-49C9F1572686Q39021652-8D756AA7-ED89-41A9-9AE3-0BFA167544D6Q39113324-8AEF8306-4959-4866-B664-9A2B9F57F42BQ39162763-F2FE7C65-ECAB-466A-A421-F596EE90C116Q39588375-5C4BF828-7DE0-4939-B815-D6FB0261BAB1Q39751817-8622D190-E305-43BE-AFAA-DBA4D941B3D0Q39898672-5133FD03-0ACA-49DF-95B6-696A32858148Q39998359-35B19FFD-4C21-41F7-A0A7-4910FB73350EQ40149288-1F5F24AC-68D8-4D74-A15F-92CDF7463B4DQ40610363-B02E479E-1CF7-46AD-BA5B-CDAA8B7B89C7Q40701711-F04A218A-8DB3-4EF1-B57D-52E33BAE323FQ40814248-3EAD3CCB-A571-471A-9467-C288616062C1Q41229162-6DACB214-5770-4110-9AF4-6A826ABDB242Q42472084-FEE2DAF1-0202-4DB3-827D-051A4D1F26F6Q42805238-9F029BED-F3FB-446D-A71F-C0BF94CE454EQ42834571-392F99FD-56B1-4AC7-AF2B-4A38BA37D943Q44319715-1955E376-4541-4642-9064-83C92847D36EQ47263261-4243B400-0A12-4014-90DA-032A8664D781Q47739870-9CC0728E-016D-42C6-B8A9-2D4CA8E35730Q52574991-0BC3EF6F-7A0C-4F1D-BCFB-B46F63E3D6F0Q52871904-5E2F8BF5-E42E-4957-9C65-17A5D499651BQ57748874-72CCDBF8-AEA8-42D5-BA54-E539427898E8Q61968828-8DD9B705-BBA1-4042-B64C-035541D7B40EQ63185439-83FCDDAE-83A0-4E3D-827F-9A14C6A26AC4Q68362182-C297DD67-6771-499A-B4B9-994830C1E753Q77922880-22A6C2EA-2F69-4ACF-93FA-442BC1F23DFAQ79156655-1A6A04D6-B14E-4B8C-A729-335DE1200BF8Q79970294-3CC2E74C-EA22-4F5A-BC32-114778A8DA9E
P50
description
forsker
@nb
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8778-7931
@en
name
L. Cleris
@ast
L. Cleris
@nl
Loredana Cleris
@en
Loredana Cleris
@es
Loredana Cleris
@nb
type
label
L. Cleris
@ast
L. Cleris
@nl
Loredana Cleris
@en
Loredana Cleris
@es
Loredana Cleris
@nb
altLabel
L. Cleris
@en
prefLabel
L. Cleris
@ast
L. Cleris
@nl
Loredana Cleris
@en
Loredana Cleris
@es
Loredana Cleris
@nb
P106
P1153
6602072163
P31
P496
0000-0001-8778-7931